Takeda Pharmaceutical Co. Ltd. - Stock Based Compensation

Takeda Pharmaceutical Co. Ltd.'s Fiscal Year is From April To March - All Figures are in JPY, Billions.

The item "Stock-Based-Compensation" stands at 71.19 Billion Japanese Yens for the trailing twelve months (TTM) period ending 09/30/2025, the lowest value since 09/30/2024.

Takeda Pharmaceutical Co. Ltd.'s second quarter result of 18.73 Billion JPY for the item "Stock Based Compensation" represents an increase of 13.31 percent compared to it's first quarter result.

Also, Takeda Pharmaceutical Co. Ltd.'s second quarter result of 18.73 Billion JPY for the item "Stock Based Compensation" represents a decrease of -13.10 percent compared to it's second quarter result of last year.

Looking again at the trailing twelve months series (TTM), Takeda Pharmaceutical Co. Ltd.'s second quarter result of 71.19 Billion JPY for the item "Stock Based Compensation" represents a decrease of -3.81 percent compared to it's first quarter result.


Regarding the One-Year-Change of the series, the current value constitutes a decrease of -3.58 percent compared to the value the year prior.
The 1 year change in percent is -3.58.
The 3 year change in percent is 37.60.
The 5 year change in percent is 111.27.
The 10 year change in percent is 249.82.

The Serie's long term average value is 37.60 Billion Japanese Yens. It's latest available value, on 09/30/2025, is 89.35 percent higher, compared to it's long term average value.
The Serie's change in percent from it's minimum value, on 03/31/2018, to it's latest available value, on 09/30/2025, is +739.10%.
The Serie's change in percent from it's maximum value, on 06/30/2025, to it's latest available value, on 09/30/2025, is -3.81%.